{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:00:52Z","timestamp":1790136052506,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T00:00:00Z","timestamp":1323302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/bjc.2011.532","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T23:50:35Z","timestamp":1323388235000},"page":"116-125","source":"Crossref","is-referenced-by-count":83,"title":["Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide"],"prefix":"10.1038","volume":"106","author":[{"given":"J","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D S","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Gillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Schiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E D","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,8]]},"reference":[{"key":"BFbjc2011532_CR1","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","volume":"1","author":"C Arce","year":"2006","unstructured":"Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramirez T, Vela T, Candelaria M, Camargo MF, Robles E, Duenas-Gonzalez A (2006) A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 1: e98","journal-title":"PLoS One"},{"key":"BFbjc2011532_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/b703830p","volume":"37","author":"AV Bieliauskas","year":"2008","unstructured":"Bieliauskas AV, Pflum MK (2008) Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 37: 1402\u20131413","journal-title":"Chem Soc Rev"},{"key":"BFbjc2011532_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2011532_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, Gonzalez-Fierro A, Chavez-Blanco A, de la Cruz-Hernandez E, Camargo MF, Trejo-Becerril C, Perez-Cardenas E, Perez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Duenas-Gonzalez A (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18: 1529\u20131538","journal-title":"Ann Oncol"},{"key":"BFbjc2011532_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ijc.22073","volume":"120","author":"JP Cantor","year":"2007","unstructured":"Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, McCorkell KA, Lakshman TV, Collins JE, Wachsberger P, Friedberg JS, Huebner K (2007) Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer 120: 24\u201331","journal-title":"Int J Cancer"},{"key":"BFbjc2011532_CR6","doi-asserted-by":"publisher","first-page":"38879","DOI":"10.1074\/jbc.M505733200","volume":"280","author":"CS Chen","year":"2005","unstructured":"Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879\u201338887","journal-title":"J Biol Chem"},{"key":"BFbjc2011532_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier CR, Cairns BR (2009) The biology of chromatin remodeling complexes. Annu Rev Biochem 78: 273\u2013304","journal-title":"Annu Rev Biochem"},{"key":"BFbjc2011532_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bcp.2008.06.004","volume":"76","author":"SJ Crabb","year":"2008","unstructured":"Crabb SJ, Howell M, Rogers H, Ishfaq M, Yurek-George A, Carey K, Pickering BM, East P, Mitter R, Maeda S, Johnson PW, Townsend P, Shin-ya K, Yoshida M, Ganesan A, Packham G (2008) Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem Pharmacol 76: 463\u2013475","journal-title":"Biochem Pharmacol"},{"key":"BFbjc2011532_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00726-004-0087-3","volume":"26","author":"E Di Gennaro","year":"2004","unstructured":"Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A (2004) Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26: 435\u2013441","journal-title":"Amino Acids"},{"key":"BFbjc2011532_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111\u20131120","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbjc2011532_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tig.2005.08.009","volume":"21","author":"K Ekwall","year":"2005","unstructured":"Ekwall K (2005) Genome-wide analysis of HDAC function. Trends Genet 21: 608\u2013615","journal-title":"Trends Genet"},{"key":"BFbjc2011532_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1023\/B:APPT.0000038036.31271.50","volume":"9","author":"F Facchetti","year":"2004","unstructured":"Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA (2004) Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9: 573\u2013582","journal-title":"Apoptosis"},{"key":"BFbjc2011532_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1139\/o01-116","volume":"79","author":"W Fischle","year":"2001","unstructured":"Fischle W, Kiermer V, Dequiedt F, Verdin E (2001) The emerging role of class II histone deacetylases. Biochem Cell Biol 79: 337\u2013348","journal-title":"Biochem Cell Biol"},{"key":"BFbjc2011532_CR14","doi-asserted-by":"publisher","first-page":"D652","DOI":"10.1093\/nar\/gkp995","volume":"38","author":"SA Forbes","year":"2010","unstructured":"Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652\u2013D657","journal-title":"Nucleic Acids Res"},{"key":"BFbjc2011532_CR15","first-page":"4916","volume":"62","author":"R Furumai","year":"2002","unstructured":"Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916\u20134921","journal-title":"Cancer Res"},{"key":"BFbjc2011532_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2174\/138161208783885335","volume":"14","author":"Y Itoh","year":"2008","unstructured":"Itoh Y, Suzuki T, Miyata N (2008) Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 14: 529\u2013544","journal-title":"Curr Pharm Des"},{"key":"BFbjc2011532_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2174\/138161208783885317","volume":"14","author":"P Jones","year":"2008","unstructured":"Jones P, Steinkuhler C (2008) From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des 14: 545\u2013561","journal-title":"Curr Pharm Des"},{"key":"BFbjc2011532_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/ncponc0106","volume":"2","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, Marks PA (2005) Drug insight: Histone deacetylase inhibitors \u2013 development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150\u2013157","journal-title":"Nat Clin Pract Oncol"},{"key":"BFbjc2011532_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00008390-200506000-00002","volume":"15","author":"DD Klisovic","year":"2005","unstructured":"Klisovic DD, Klisovic MI, Effron D, Liu S, Marcucci G, Katz SE (2005) Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma. Melanoma Res 15: 147\u2013153","journal-title":"Melanoma Res"},{"key":"BFbjc2011532_CR20","first-page":"3429","volume":"26","author":"KW Lee","year":"2006","unstructured":"Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ (2006) Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 26: 3429\u20133438","journal-title":"Anticancer Res"},{"key":"BFbjc2011532_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/med.20056","volume":"26","author":"HY Lin","year":"2006","unstructured":"Lin HY, Chen CS, Lin SP, Weng JR, Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397\u2013413","journal-title":"Med Res Rev"},{"key":"BFbjc2011532_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129\u20132139","journal-title":"N Engl J Med"},{"key":"BFbjc2011532_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11010-009-0116-3","volume":"329","author":"JC Marshall","year":"2009","unstructured":"Marshall JC, Lee JH, Steeg PS (2009) Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. Mol Cell Biochem 329: 115\u2013120","journal-title":"Mol Cell Biochem"},{"key":"BFbjc2011532_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bcp.2004.05.034","volume":"68","author":"F McLaughlin","year":"2004","unstructured":"McLaughlin F, La Thangue NB (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68: 1139\u20131144","journal-title":"Biochem Pharmacol"},{"key":"BFbjc2011532_CR25","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1535-7163.MCT-07-2140","volume":"7","author":"A Miyanaga","year":"2008","unstructured":"Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7: 1923\u20131930","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2011532_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.athoracsur.2005.06.059","volume":"81","author":"NK Mukhopadhyay","year":"2006","unstructured":"Mukhopadhyay NK, Weisberg E, Gilchrist D, Bueno R, Sugarbaker DJ, Jaklitsch MT (2006) Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann Thorac Surg 81: 1034\u20131042","journal-title":"Ann Thorac Surg"},{"key":"BFbjc2011532_CR27","first-page":"4460","volume":"63","author":"MJ Peart","year":"2003","unstructured":"Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O\u2019Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460\u20134471","journal-title":"Cancer Res"},{"key":"BFbjc2011532_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcb.240630505","volume":"24","author":"RM Phelps","year":"1996","unstructured":"Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn Jr PA, Carney D, Minna JD, Mulshine JL (1996) NCI-navy medical oncology branch cell line data base. J Cell Biochem Suppl 24: 32\u201391","journal-title":"J Cell Biochem Suppl"},{"key":"BFbjc2011532_CR29","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","volume":"15","author":"HM Prince","year":"2009","unstructured":"Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958\u20133969","journal-title":"Clin Cancer Res"},{"key":"BFbjc2011532_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molcel.2006.04.019","volume":"22","author":"Y Qiu","year":"2006","unstructured":"Qiu Y, Zhao Y, Becker M, John S, Parekh BS, Huang S, Hendarwanto A, Martinez ED, Chen Y, Lu H, Adkins NL, Stavreva DA, Wiench M, Georgel PT, Schiltz RL, Hager GL (2006) HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 22: 669\u2013679","journal-title":"Mol Cell"},{"key":"BFbjc2011532_CR31","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1158\/0008-5472.CAN-04-3703","volume":"64","author":"RD Ramirez","year":"2004","unstructured":"Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027\u20139034","journal-title":"Cancer Res"},{"key":"BFbjc2011532_CR32","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1167\/iovs.03-1285","volume":"45","author":"DH Ren","year":"2004","unstructured":"Ren DH, Mayhew E, Hay C, Li H, Alizadeh H, Niederkorn JY (2004) Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci 45: 1162\u20131168","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFbjc2011532_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00253-007-0912-1","volume":"75","author":"D Riester","year":"2007","unstructured":"Riester D, Hildmann C, Schwienhorst A (2007) Histone deacetylase inhibitors \u2013 turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol 75: 499\u2013514","journal-title":"Appl Microbiol Biotechnol"},{"key":"BFbjc2011532_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","volume":"100","author":"A Rocca","year":"2009","unstructured":"Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nole F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A (2009) A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 100: 28\u201336","journal-title":"Br J Cancer"},{"key":"BFbjc2011532_CR35","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","volume":"23","author":"QC Ryan","year":"2005","unstructured":"Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912\u20133922","journal-title":"J Clin Oncol"},{"key":"BFbjc2011532_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.biochi.2007.06.009","volume":"90","author":"K Sadoul","year":"2008","unstructured":"Sadoul K, Boyault C, Pabion M, Khochbin S (2008) Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90: 306\u2013312","journal-title":"Biochimie"},{"key":"BFbjc2011532_CR37","first-page":"718","volume":"8","author":"V Sandor","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718\u2013728","journal-title":"Clin Cancer Res"},{"key":"BFbjc2011532_CR38","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/0008-5472.CAN-05-2521","volume":"66","author":"M Sato","year":"2006","unstructured":"Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, Minna JD (2006) Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116\u20132128","journal-title":"Cancer Res"},{"key":"BFbjc2011532_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3816\/CLC.2002.n.027","volume":"4","author":"DS Schrump","year":"2002","unstructured":"Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y (2002) Phase I study of sequential deoxyazacytidine\/depsipeptide infusion in patients with malignancies involving lungs or pleura. Clin Lung Cancer 4: 186\u2013192","journal-title":"Clin Lung Cancer"},{"key":"BFbjc2011532_CR40","doi-asserted-by":"publisher","first-page":"11083","DOI":"10.1021\/bi0494471","volume":"43","author":"BE Schultz","year":"2004","unstructured":"Schultz BE, Misialek S, Wu J, Tang J, Conn MT, Tahilramani R, Wong L (2004) Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 43: 11083\u201311091","journal-title":"Biochemistry"},{"key":"BFbjc2011532_CR41","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1371\/journal.pmed.0030486","volume":"3","author":"DS Shames","year":"2006","unstructured":"Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486","journal-title":"PLoS Med"},{"key":"BFbjc2011532_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2009.03.016","volume":"280","author":"L Stimson","year":"2009","unstructured":"Stimson L, La Thangue NB (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280: 177\u2013183","journal-title":"Cancer Lett"},{"key":"BFbjc2011532_CR43","doi-asserted-by":"publisher","first-page":"458431","DOI":"10.1155\/2010\/458431","volume":"2010","author":"N Takai","year":"2010","unstructured":"Takai N, Narahara H (2010) Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010: 458431","journal-title":"J Oncol"},{"key":"BFbjc2011532_CR44","first-page":"971","volume":"7","author":"DM Vigushin","year":"2001","unstructured":"Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971\u2013976","journal-title":"Clin Cancer Res"},{"key":"BFbjc2011532_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.20372","volume":"112","author":"A Villar-Garea","year":"2004","unstructured":"Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171\u2013178","journal-title":"Int J Cancer"},{"key":"BFbjc2011532_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277: 8\u201321","journal-title":"Cancer Lett"},{"key":"BFbjc2011532_CR47","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1128\/MCB.01516-07","volume":"28","author":"LP Wu","year":"2008","unstructured":"Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, Zhou W, Liu X, Yang J, Zheng Z, Zhang H, Feng J, Yang Y, Wang H, Zhu WG (2008) Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 28: 3219\u20133235","journal-title":"Mol Cell Biol"},{"key":"BFbjc2011532_CR48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/rcm.976","volume":"17","author":"JJ Xiao","year":"2003","unstructured":"Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK (2003) Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom 17: 757\u2013766","journal-title":"Rapid Commun Mass Spectrom"},{"key":"BFbjc2011532_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/JTO.0b013e318194fae7","volume":"4","author":"W Zhang","year":"2009","unstructured":"Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP (2009) Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 4: 161\u2013166","journal-title":"J Thorac Oncol"},{"key":"BFbjc2011532_CR50","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.4161\/cbt.7.9.6415","volume":"7","author":"XH Zhang","year":"2008","unstructured":"Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS (2008) Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7: 1388\u20131397","journal-title":"Cancer Biol Ther"},{"key":"BFbjc2011532_CR51","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1128\/MCB.26.7.2782-2790.2006","volume":"26","author":"Y Zhao","year":"2006","unstructured":"Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG (2006) Acetylation of p53 at lysine 373\/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1\/Cip1). Mol Cell Biol 26: 2782\u20132790","journal-title":"Mol Cell Biol"},{"key":"BFbjc2011532_CR52","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/sj.onc.1210041","volume":"26","author":"S Zhong","year":"2007","unstructured":"Zhong S, Fields CR, Su N, Pan YX, Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621\u20132634","journal-title":"Oncogene"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011532","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:05:34Z","timestamp":1684415134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,8]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFbjc2011532"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.532","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,8]]}}}